US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.

Apple tree
The FDA's Peter Marks says an upcoming guidance will address both the low- and higher-hanging fruit when it comes to scenarios for accelerated approval of gene therapies. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies